Vistagen to Present at Psych Congress 2026
Vistagen, a Nasdaq-listed biopharmaceutical company, announced it will present encouraging efficacy data from its Phase 3 trials of fasedienol nasal spray for very severe social anxiety disorder at Psych Congress 2026. The intranasal product aims to offer rapid therapeutic benefits via a novel pherine mechanism targeting nose-to-brain neurocircuitr…